S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
APYX · Apyx Medical Corporation
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$2.50
+0.08
(+3.51%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.50
$2.46
$2.50
52-WEEK RANGE
$2.50
$2.32
$5.08
What's happening
- APYX is up 3.51% today, trading at $2.50. — Live quote
- Volume today (2,818) is well below its 3-month average of 126,010. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (before market open), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.07 actual vs. $-0.08 estimated (+16.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
APYX
-30.86%
vs S&P 500
-43.26%
1-YEAR RETURN
APYX
-17.12%
vs S&P 500
-32.49%
6-MONTH RETURN
APYX
-37.95%
3-MONTH RETURN
APYX
-40.54%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.07
Est. $-0.08
BEAT +16.3%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.11
BEAT +53.7%
2026-01-26 (Q4 2025)
$-0.03
Est. $-0.06
BEAT +48.6%
2025-10-26 (Q3 2025)
$-0.05
Est. $-0.10
BEAT +52.2%
Valuation Measures & Ratios
Enterprise Value4$112.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1.79
Price / Book717.65
EV4 / Revenue1.92
EV4 / EBITDA162.92
Profit Margin-14.78%
Operating Margin-6.06%
Return on Equity (ROE8)-78.70%
Return on Assets (ROA9)-13.91%
Avg Volume (3M)126,010
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short206,825
Change from Prior Settlement-5.15%
% of Float—
Days to Cover (Short Ratio)1.17
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 22.1% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -14.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -17.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on APYX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.9M | $12.5M | $12.9M | $11.4M | $9.4M | $11.5M | $12.1M | $10.2M |
| Gross profit | $8.9M | $7.9M | $8.3M | $7.1M | $5.7M | $7.0M | $7.5M | $5.9M |
| Operating income | -$1.8M | -$911.0K | -$832.0K | -$2.6M | -$3.1M | -$3.6M | -$5.5M | -$6.6M |
| Net income | -$3.2M | -$2.1M | -$2.0M | -$3.8M | -$4.2M | -$4.7M | -$6.6M | -$7.6M |
| EPS (diluted) | — | — | — | — | — | — | $-0.19 | $-0.22 |
| EPS (basic) | $-0.07 | $-0.05 | $-0.05 | $-0.09 | $-0.10 | $-0.14 | $-0.19 | $-0.22 |
| Operating margin | -$13 | -$7 | -$6 | -$23 | -$32 | -$32 | -$46 | -$65 |
| Net margin | -$23 | -$17 | -$15 | -$33 | -$44 | -$41 | -$54 | -$74 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $61.1M | $63.0M | $66.8M | $57.4M | $58.2M | $60.2M | $64.8M | $60.7M |
| Total liabilities | $50.0M | $49.9M | $52.0M | $51.3M | $50.7M | $49.5M | $50.5M | $49.5M |
| Stockholders' equity | $10.7M | $12.8M | $14.5M | $5.8M | $7.3M | $10.5M | $14.2M | $11.0M |
| Total current assets | $53.2M | $54.8M | $58.5M | $48.8M | $49.9M | $51.9M | $56.4M | $52.2M |
| Total current liabilities | $9.4M | $9.4M | $11.7M | $11.0M | $10.6M | $9.5M | $10.7M | $9.6M |
| Cash & equivalents | $27.6M | $31.1M | $31.7M | $25.1M | $29.3M | $31.0M | $31.7M | $28.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $13.6M | $12.8M | $16.8M | $13.0M | $11.2M | $11.6M | $15.5M | $13.0M |
| Inventory | $10.7M | $9.5M | $8.6M | $9.1M | $8.2M | $7.7M | $7.6M | $9.0M |
| Property, plant & equipment | $2.1M | $2.2M | $2.4M | $2.4M | $2.0M | $1.9M | $2.0M | $1.9M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $1.8M | $1.9M | $1.8M | $1.8M | $1.7M | $1.8M | $1.7M | $1.8M |
| Accounts payable | $2.2M | $2.6M | $3.1M | $3.2M | $2.9M | $2.3M | $2.6M | $1.9M |
| Accrued liabilities | $6.7M | $6.4M | $8.2M | $7.3M | $7.3M | $6.8M | $7.8M | $7.3M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $35.3M | $35.1M | $34.8M | $34.6M | $34.4M | $34.1M | $33.9M | $33.9M |
| Other non-current liabilities | $336.0K | $339.0K | $347.0K | $293.0K | $292.0K | $270.0K | $259.0K | $201.0K |
| Common stock & paid-in capital | $42.0K | $42.0K | $42.0K | $38.0K | $38.0K | $38.0K | $38.0K | $35.0K |
| Retained earnings | -$94.5M | -$91.2M | -$89.1M | -$87.8M | -$85.8M | -$82.1M | -$77.9M | -$73.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.5M | -$572.0K | -$2.5M | -$3.5M | -$1.2M | -$702.0K | -$2.9M | -$4.4M |
| Investing cash flow | -$66.0K | -$60.0K | -$275.0K | -$519.0K | -$265.0K | -$55.0K | -$245.0K | -$153.0K |
| Financing cash flow | -$5.0K | $83.0K | $9.5M | $45.0K | $25.0K | $25.0K | $6.8M | -$5.0K |
| Free cash flow | -$3.6M | -$632.0K | -$2.8M | -$4.1M | -$1.5M | -$757.0K | -$3.2M | -$4.6M |
| Capital expenditures | $66.0K | $60.0K | $275.0K | $519.0K | $265.0K | $55.0K | $245.0K | $153.0K |
| Depreciation & amortization | $196.0K | $202.0K | $221.0K | $164.0K | $132.0K | $138.0K | $142.0K | $144.0K |
| Share-based compensation | $1.1M | $312.0K | $500.0K | $530.0K | $520.0K | $451.0K | $838.0K | $997.0K |
| Deferred income taxes | — | — | — | — | — | — | -$4.3M | — |
| Change in accounts receivable | $946.0K | -$4.0M | $3.9M | $1.8M | -$471.0K | -$3.9M | $2.9M | $308.0K |
| Change in inventory | $1.3M | $845.0K | -$511.0K | $865.0K | $521.0K | $199.0K | -$1.4M | -$355.0K |
| Change in accounts payable | -$444.0K | -$411.0K | -$155.0K | $328.0K | $513.0K | -$331.0K | $756.0K | -$474.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | $0 | $0 |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M |
| Gross profit | $33.0M | $29.4M | $33.8M | $29.1M | $33.6M |
| Operating income | -$6.4M | -$18.8M | -$17.3M | -$23.6M | -$14.4M |
| Net income | -$11.2M | -$23.5M | -$18.7M | -$23.2M | -$15.2M |
| EPS (diluted) | — | — | $-0.54 | $-0.67 | $-0.44 |
| EPS (basic) | $-0.27 | $-0.66 | $-0.54 | $-0.67 | $-0.44 |
| Operating margin | -$12 | -$39 | -$33 | -$53 | -$30 |
| Net margin | -$21 | -$49 | -$36 | -$52 | -$31 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $66.8M | $64.8M | $79.2M | $51.8M | $68.7M |
| Total liabilities | $52.0M | $50.5M | $52.3M | $14.0M | $14.7M |
| Stockholders' equity | $14.5M | $14.2M | $26.7M | $37.6M | $53.7M |
| Total current assets | $58.5M | $56.4M | $70.4M | $43.0M | $60.7M |
| Total current liabilities | $11.7M | $10.7M | $12.7M | $11.8M | $13.2M |
| Cash & equivalents | $31.7M | $31.7M | $43.7M | $10.2M | $30.9M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $16.8M | $15.5M | $14.0M | $10.6M | $13.0M |
| Inventory | $8.6M | $7.6M | $9.9M | $11.8M | $6.8M |
| Property, plant & equipment | $2.4M | $2.0M | $1.9M | $6.8M | $6.6M |
| Goodwill | — | — | — | — | — |
| Other non-current assets | $1.8M | $1.7M | $1.7M | $1.2M | $1.1M |
| Accounts payable | $3.1M | $2.6M | $2.7M | $2.7M | $2.6M |
| Accrued liabilities | $8.2M | $7.8M | $9.7M | $8.9M | $10.3M |
| Deferred revenue (current) | — | — | $500.0K | $900.0K | $500.0K |
| Short-term debt | — | — | — | — | — |
| Long-term debt | $34.8M | $33.9M | $33.2M | $0 | — |
| Other non-current liabilities | $347.0K | $259.0K | $198.0K | $181.0K | $166.0K |
| Common stock & paid-in capital | $42.0K | $38.0K | $35.0K | $35.0K | $34.0K |
| Retained earnings | -$89.1M | -$77.9M | -$54.4M | -$35.7M | -$12.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$8.0M | -$18.0M | -$5.2M | -$20.3M | -$10.4M |
| Investing cash flow | -$1.1M | -$722.0K | $6.7M | -$1.0M | -$723.0K |
| Financing cash flow | $9.6M | $6.7M | $32.2M | $217.0K | $24.0K |
| Free cash flow | -$9.1M | -$18.8M | -$5.8M | -$21.3M | -$11.2M |
| Capital expenditures | $1.1M | $722.0K | $533.0K | $1.0M | $723.0K |
| Depreciation & amortization | $655.0K | $599.0K | $692.0K | $890.0K | $903.0K |
| Share-based compensation | $2.0M | $4.0M | $5.1M | $6.7M | $5.1M |
| Deferred income taxes | — | -$4.3M | -$4.4M | -$5.1M | -$3.1M |
| Change in accounts receivable | $1.3M | $2.0M | $3.6M | -$1.9M | $4.9M |
| Change in inventory | $1.1M | -$2.3M | -$1.5M | $5.6M | $2.9M |
| Change in accounts payable | $355.0K | -$63.0K | $25.0K | $67.0K | $1.2M |
| Purchases of investments | — | — | — | — | — |
| Debt issued | — | $0 | $43.5M | $0 | — |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding APYX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-27 to 2026-06-30
Recent transactions
- Most recent: Waldman Lawrence (Director) — Option exercise of 12,000 shares on 2026-06-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Waldman Lawrence | Director | Option exercise | 2026-06-30 | 12,000 |
| Roman Shawn David | Chief Operating Officer | Option exercise | 2026-06-15 | 15,000 |
| Vizirgianakis Stavros G. | Director | Grant / award | 2026-06-11 | 450,000 |
| CITRONOWICZ MOSHE | Senior Vice President | Option exercise | 2026-03-15 | 37,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-30 | Waldman Lawrence | Director | Option exercise | 12,000 | $1.88 |
| 2026-06-30 | Waldman Lawrence | Director | Tax withholding | 5,024 | $4.49 |
| 2026-06-15 | Roman Shawn David | Chief Operating Officer | Option exercise | 15,000 | $3.23 |
| 2026-06-15 | Roman Shawn David | Chief Operating Officer | Tax withholding | 10,533 | $4.60 |
| 2026-06-11 | Vizirgianakis Stavros G. | Director | Grant / award | 450,000 | $0.00 |
| 2026-03-15 | CITRONOWICZ MOSHE | Senior Vice President | Option exercise | 37,000 | $1.80 |
| 2026-01-27 | Roman Shawn David | Chief Operating Officer | Option exercise | 12,000 | $1.80 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-24 | 8-K | 2026-07-24 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about APYX (Apyx Medical Corporation). Links open the publisher — we don’t host full articles.
-
Apyx Medical Corporation to Participate in Upcoming Investor Conferences
Yahoo · 2026-10-21 -
You can watch two Apyx Medical events live in November
Stock Titan · 2026-10-21 -
Live Apyx Medical Corporation (APYX) Technical Analysis
Traders Union · 2026-10-16 -
Apyx Medical Corporation Stock Price Prediction: Today, Tomorrow, Next Week (APYX)
Traders Union · 2026-10-15 -
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Yahoo Finance · 2026-09-29 -
Cold Plasma Market Forecasts Growth from $3.32B (2025) to $8.45B by 2032, Profiling Nordson Corporation, Apyx Medical, Plasmatreat & Enercon Industries
Yahoo Finance · 2026-09-24 -
Apyx Medical: Negative Cash Flow And High Valuation
Seeking Alpha · 2026-09-21 -
Cold Plasma Market Forecasts Growth from $167.8M (2025) to $495.9M by 2033, Profiling Apyx Medical, Neoplas Med, Adtec Healthcare & 5 Other Key Players
Yahoo Finance · 2026-09-15
No headlines in this category right now — try “All”.